Literature DB >> 32312763

Differential Regulation of l-Arginine Metabolism through Arginase 1 during Infection with Leishmania mexicana Isolates Obtained from Patients with Localized and Diffuse Cutaneous Leishmaniasis.

Arturo A Wilkins-Rodríguez1, Armando Pérez-Torres2, Alma R Escalona-Montaño1, Laila Gutiérrez-Kobeh3.   

Abstract

l-Arginine metabolism through arginase 1 (Arg-1) and inducible nitric oxide synthase (NOS2) constitutes a fundamental axis for the resolution or progression of leishmaniasis. Infection with Leishmania mexicana can cause two distinct clinical manifestations: localized cutaneous leishmaniasis (LCL) and diffuse cutaneous leishmaniasis (DCL). In this work, we analyzed in an in vivo model the capacity of two L. mexicana isolates, one obtained from a patient with LCL and the other from a patient with DCL, to regulate the metabolism of l-arginine through Arg-1 and NOS2. Susceptible BALB/c mice were infected with L. mexicana isolates from both clinical manifestations, and the evolution of the infection as well as protein presence and activity of Arg-1 and NOS2 were evaluated. The lesions of mice infected with the DCL isolate were bigger, had higher parasite loads, and showed greater protein presence and enzymatic activity of Arg-1 than the lesions of mice infected with the LCL isolate. In contrast, NOS2 protein synthesis was poorly or not induced in the lesions of mice infected with the LCL or DCL isolate. The immunochemistry analysis of the lesions allowed the identification of highly parasitized macrophages positive for Arg-1, while no staining for NOS2 was found. In addition, we observed in lesions of patients with DCL macrophages with higher parasite loads and stronger Arg-1 staining than those in lesions of patients with LCL. Our results suggest that L. mexicana isolates obtained from patients with LCL or DCL exhibit different virulence or pathogenicity degrees and differentially regulate l-arginine metabolism through Arg-1.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  zzm321990l-arginine; Leishmania mexicanazzm321990; NOS2; arginase 1; diffuse cutaneous leishmaniasis; localized cutaneous leishmaniasis

Mesh:

Substances:

Year:  2020        PMID: 32312763      PMCID: PMC7309628          DOI: 10.1128/IAI.00963-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  75 in total

1.  Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major.

Authors:  A Gaafar; B Veress; H Permin; A Kharazmi; T G Theander; A M el Hassan
Journal:  Clin Immunol       Date:  1999-06       Impact factor: 3.969

2.  Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.

Authors:  C Kébaïer; H Louzir; M Chenik; A Ben Salah; K Dellagi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype.

Authors:  M Munder; K Eichmann; M Modolell
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

4.  Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.

Authors:  Lucia E Rosas; Tracy Keiser; Joseph Barbi; Anjali A Satoskar; Alecia Septer; Jennifer Kaczmarek; Claudio M Lezama-Davila; Abhay R Satoskar
Journal:  Int Immunol       Date:  2005-09-02       Impact factor: 4.823

5.  Determination of arginase activity in macrophages: a micromethod.

Authors:  I M Corraliza; M L Campo; G Soler; M Modolell
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

6.  Regulation of the expression of nitric oxide synthase by Leishmania mexicana amastigotes in murine dendritic cells.

Authors:  Arturo A Wilkins-Rodríguez; Alma Reyna Escalona-Montaño; Magdalena Aguirre-García; Ingeborg Becker; Laila Gutiérrez-Kobeh
Journal:  Exp Parasitol       Date:  2010-07-24       Impact factor: 2.011

Review 7.  Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions.

Authors:  R Etges; I Müller
Journal:  J Mol Med (Berl)       Date:  1998-05       Impact factor: 4.599

Review 8.  Arginase in Leishmania.

Authors:  Maria Fernanda Laranjeira da Silva; Lucile Maria Floeter-Winter
Journal:  Subcell Biochem       Date:  2014

9.  Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines.

Authors:  M Modolell; I M Corraliza; F Link; G Soler; K Eichmann
Journal:  Eur J Immunol       Date:  1995-04       Impact factor: 5.532

10.  Leishmania amazonensis arginase compartmentalization in the glycosome is important for parasite infectivity.

Authors:  Maria Fernanda Laranjeira da Silva; Ricardo Andrade Zampieri; Sandra M Muxel; Stephen M Beverley; Lucile M Floeter-Winter
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

View more
  3 in total

Review 1.  Polyamine Metabolism in Leishmania Parasites: A Promising Therapeutic Target.

Authors:  Nicola S Carter; Yumena Kawasaki; Surbhi S Nahata; Samira Elikaee; Sara Rajab; Leena Salam; Mohammed Y Alabdulal; Kelli K Broessel; Forogh Foroghi; Alyaa Abbas; Reyhaneh Poormohamadian; Sigrid C Roberts
Journal:  Med Sci (Basel)       Date:  2022-04-22

2.  Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism.

Authors:  Christian Bogdan
Journal:  Cytokine X       Date:  2020-10-12

3.  Leishmania amazonensis Promastigotes or Extracellular Vesicles Modulate B-1 Cell Activation and Differentiation.

Authors:  Natasha Ferraz de Campos Reis; Talita Vieira Dupin; Carolina Rizzaro Costa; Maytê Dos Santos Toledo; Vivian Cristina de Oliveira; Ana Flavia Popi; Ana Claudia Torrecilhas; Patricia Xander
Journal:  Front Cell Infect Microbiol       Date:  2020-10-30       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.